SEC Form 10-Q filed by 60 Degrees Pharmaceuticals Inc.
$SXTP
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)
4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)
4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)
Further validates continuation of the B-FREE Study to evaluate the efficacy and safety of ARAKODA® (tafenoquine) for treatment of chronic babesiosisData support theory among specialists that Babesia infection may prolong recovery times in patients with chronic fatigue WASHINGTON, Dec. 29, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that infection with Babesia, a parasite that causes the emerging tick-borne illness called babesiosis, was found in 24 percent of a cohort of 50 patients with chronic fatigue in a stu
6-month commercial pilot demonstrated increasing demand among prescribersExpansion plan includes doubling the number of sales reps, a new GoodRx partnership, and enhanced digital marketing campaignAdditional clinical sites in ongoing babesiosis treatment trials will be initiated in light of FDA feedback regarding Company's breakthrough therapy designation request WASHINGTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today the planned expansion of the Company's sales and marketing initiatives after encour
90-day trial will measure change in general fatigue in patients with chronic babesiosis following tafenoquine treatmentStudy will run approximately 12 months and enroll up to 100 patientsInternal estimates of the unmet medical need are between 4,400 and 190,000 cases annually, with no existing FDA-approved treatment for babesiosis WASHINGTON, Nov. 21, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today that the central study site for the Company's B-FREE Chronic Babesiosis Study, the Cohen Center for Recovery from Comple
4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)
4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)
4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)
8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)
SCHEDULE 13G/A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)
10-Q - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)
SC 13G - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)
SC 13G/A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)
SC 13G/A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)
ORLANDO, FL / ACCESSWIRE / December 2, 2024 / RedChip Companies aired interviews with VSee Health, Inc. (NASDAQ:VSEE) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV on November 30. Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:VSEE: https://www.redchip.com/assets/access/vsee_accessSXTP: https://www.redchip.com/assets/access/sxtp_accessIn an exclusive interview, Imo Aisiku, M.D., co-CEO and Chairman of VSee Health, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to share insight into how VSee Health's differentiated so
ORLANDO, FL / ACCESSWIRE / November 22, 2024 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) and Can-Fite BioPharma Ltd. (NYSE:CANF)(TASE:CANF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, November 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:SXTP: https://www.redchip.com/assets/access/sxtp_accessCANF: https://www.redchip.com/assets/access/canf_accessIn an exclusive interview, Geoffrey Dow, CEO and President of 60 Degrees Pharmaceuticals, appears on the RedChip Small Stocks Big Money™ show on
MELBOURNE, Australia, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is pleased to advise that RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and 60 Degrees Pharmaceuticals (60P) (NASDAQ:SXTP) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S. Access the interviews in their entirety at: • Genetic Technologies (NASDAQ:GENE): https://www.redchip.com/